BTK and B-cell chronic lymphocytic leukemia: In the recent single‐centre (The Ohio State University Comprehensive Cancer Centre), retrospective cohort study (from 2009 to 2017), Bond and colleagues reported the incidence of second cancer in ∼700 patients with CLL receiving BTK inhibitors (median age of 61, and 21% receiving acalabrutinib) [1].